North China Pharmaceutical Group Aino Co., Ltd. Safety Status Evaluation Project
Time：2012-03-12
|
From：
|
Views：318
|
Font Size：Default Big Large
|
Print
|
1. Safety evaluation project name: North China Pharmaceutical Group Aino Co., Ltd. Safety Status Evaluation Report Project
2. Safety Evaluation Project Brief Introduction: North China Pharmaceutical Group Aino Co., Ltd. (hereinafter referred to as Aino Company) was founded in 1996. It is a Sino-foreign joint venture jointly established by North China Pharmaceutical Group and British Virgin Islands Maoye Investment Co., Ltd. It is mainly engaged in the development and production of raw materials and preparations for biological agriculture and veterinary medicines. Aino Company is located at No. 31, Xingye Street, Economic and Technological Development Zone, Shijiazhuang City, Hebei Province. The company covers an area of 62618.1m2, with total assets exceeding 200 million yuan and an annual output value of 150 million yuan. Yang Dechang, the legal representative of Aino Company, has 465 employees, including 97 managers and 368 operators. The company's main products are avermectin, ivermectin original drugs and pesticide preparations, all of which started production in 1999.
3. Safety evaluation project leader, technical leader, process control leader, evaluation report compiler, report auditor, safety evaluator, registered safety engineer, and technical expert involved in the evaluation:
Safety evaluation project leader: Xu Zhe
Technical person in charge: Cao Shuhua
Person in charge of process control: Gao Weili
Evaluation Report Compilers: Xu Zhe, Sun Guang, Wang Lin
Report Reviewer: Zhang Lijuan
Safety evaluators, registered safety engineers, and technical experts participating in the evaluation work: Xu Zhe, Sun Guang, Wang Lin
4. List of personnel, time, and main tasks to carry out safety evaluation work on site, and evaluation report time:
In March 2012, North China Pharmaceutical Group Aino Co., Ltd. approached Hebei Huafei Technology Consulting Co., Ltd. to discuss the safety status evaluation work. Huafei Company appointed relevant personnel to go to the project site of North China Pharmaceutical Group Aino Co., Ltd. in February 2012 to conduct on-site inspections, understand the main equipment, production scale, general layout, public works supply and surrounding relationships of the project, and collect relevant information of the project, and make relevant risk analysis of the project. After many conferrals, the relevant personnel of the two companies formed a preliminary intention and initially clarified the object and scope of the evaluation. During the evaluation process, the members of the evaluation team carefully analyzed and sorted out the relevant materials provided by the enterprise and collected on site, identified the dangerous and harmful factors existing in the project, conducted a qualitative and quantitative evaluation of the inherent danger degree of the project according to the divided evaluation units, and analyzed the risk degree of the project, put forward targeted safety countermeasures and suggestions, and exchanged views with the construction unit, and made a safety evaluation conclusion on this basis. After solid work, the safety status evaluation report of the project was completed in March 2012.